Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Cytosorbents (CTSO) over the last 9 years, with Q3 2025 value amounting to -$0.05.

  • Cytosorbents' EPS (Weighted Average and Diluted) changed 0.0% to -$0.05 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.18, marking a year-over-year increase of 5000.0%. This contributed to the annual value of -$0.38 for FY2024, which is 4144.29% up from last year.
  • As of Q3 2025, Cytosorbents' EPS (Weighted Average and Diluted) stood at -$0.05, which was down 0.0% from $0.03 recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' EPS (Weighted Average and Diluted) registered a high of $0.03 during Q2 2025, and its lowest value of -$0.28 during Q3 2022.
  • For the 5-year period, Cytosorbents' EPS (Weighted Average and Diluted) averaged around -$0.13, with its median value being -$0.13 (2023).
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 133196.16% in 2021, then soared by 13750.0% in 2025.
  • Quarter analysis of 5 years shows Cytosorbents' EPS (Weighted Average and Diluted) stood at -$0.25 in 2021, then skyrocketed by 92.97% to -$0.02 in 2022, then crashed by 643.14% to -$0.13 in 2023, then decreased by 6.39% to -$0.14 in 2024, then skyrocketed by 64.03% to -$0.05 in 2025.
  • Its last three reported values are -$0.05 in Q3 2025, $0.03 for Q2 2025, and -$0.02 during Q1 2025.